Kristopher Bosse, MD

male silhouette icon
Kristopher Bosse, MD, is an attending physician in the Division of Oncology at Children's Hospital of Philadelphia.

Locations: Main Campus

Appointments and Referrals: 1-800-TRY-CHOP (1-800-879-2467)

Background

Despite the use of intensive multimodal therapy for neuroblastoma, approximately one-half of children still die from this disease. Dr. Bosse's laboratory focuses on the development of new immune-based therapies for this embryonal malignancy of the developing nervous system. Through these studies, Dr. Bosse and his colleagues hope to both improve their understanding of the critical biologic mechanisms driving neuroblastoma tumorigenesis and to translate new transformative immunotherapeutics to the clinic.

To this end, Dr. Bosse and his colleagues have discovered that the lineage-restricted oncoprotein, glypican-2 (GPC2), is robustly and selectively expressed on the surface of neuroblastomas and that this molecule is essential to neuroblastoma tumorigenesis. They are now focused on defining the biology of neuroblastoma’s dependence on GPC2 and developing immunotherapeutic approaches targeting GPC2, including antibody-drug conjugates and chimeric antigen receptor (CAR) T cells. Using their immunotherapeutic target discovery algorithm and validation platform, they are also developing additional differentially expressed neuroblastoma cell surface molecules for immune-based therapies. This work is done as part of the St. Baldricks-Stand Up To Cancer Immunogenomics Team.

An additional project in Dr. Bosse's laboratory is focused on the serial sequencing of circulating tumor (ctDNA) from neuroblastoma patients to define tumor heterogeneity and clonal evolution while children are receiving both conventional chemoradiotherapies and also more targeted therapeutics. Dr. Bosse anticipates these efforts may both help define a role for ctDNA profiling in the clinical care of children with neuroblastoma and other pediatric solid tumors and also identify novel mutated driver oncogenes that warrant additional functional validation.

Finally, Dr. Bosse's laboratory is also interested in defining the functional implications of neuroblastoma-associated germline genetic variation, with a particular interest in describing the role of common and rare genetic variation in the regulation of BARD1 gene expression and how these alterations collectively contribute to neuroblastoma predisposition.

Education and Training

Medical School

MD - University of Pennsylvania School of Medicine, Philadelphia, PA

Internship

Pediatrics - The Children's Hospital of Philadelphia, Philadelphia, PA

Residency

Pediatrics - The Children's Hospital of Philadelphia, Philadelphia, PA

Fellowship

Hematology/Oncology - The Children's Hospital of Philadelphia, Philadelphia, PA

Board Certification

American Academy of Pediatrics

Titles and Academic Titles

Attending Physician

Assistant Professor, Perelman School of Medicine at the University of Pennsylvania

Departments and Services

Research Interests

Functional genomics

Immunotherapeutic approaches to treating pediatric cancer

Neuroblastoma

Circulating tumor DNA (ctDNA)

Publications

Papers

2017

Bosse KR, Raman P, Zhu Z, Lane M, Martinez D, Heitzeneder S, Rathi KS, Kendsersky NM, Randall M, Donovan L, Morrissy S, Sussman RT, Zhelev DV, Feng Y, Wang Y, Hwang J, Lopez G, Harenza JL, Wei JS, Pawel B, Bhatti T, Santi M, Ganguly A, Khan J, Marra MA, Taylor MD, Dimitrov S, Mackall CL, Maris JM. Identification of GPC2 as an Oncoprotein and Candidate Immunotherapeutic Target in High-Risk Neuroblastoma. Cancer Cell. 2017;32(3):295–309. [Epub ahead of print]

2015

Martino J, Fisher BT, Bosse KR, Bagatell R. Suspected posaconazole toxicity in a pediatric oncology patient. Pediatric Blood Cancer. 2015; 62 (9): 1682.

Sterling ME, Long CJ, Bosse KR, Bagatell R, Shukla AR. A rapid progression of disease after surgical excision of a malignant rhabdoid tumor of the bladder. Urology. 2015; 85 (3): 664-6.

2016

Bosse KR and Maris JM. Advances in the translational genomics of neuroblastoma: From improving risk stratification and revealing novel biology to identifying actionable genomic alterations. Cancer. 2016; 122 (1): 20-33.

Feng Y, Wang Y, Zhu Z, Li W, Sussman RT, Randall M, Bosse KR, Maris JM, Dimitrov, DS. Differential killing of CD56-expressing cells by drug-conjugated human antibodies targeting membrane-distal and membrane-proximal non-overlapping epitopes. MAbs. 2016; 8 (4): 799-810.

2015

Martino J, Fisher BT, Bosse KR, Bagatell R. Suspected posaconazole toxicity in a pediatric oncology patient. Pediatric Blood Cancer. 2015; 62 (9): 1682.

Sterling ME, Long CJ, Bosse KR, Bagatell R, Shukla AR. A rapid progression of disease after surgical excision of a malignant rhabdoid tumor of the bladder. Urology. 2015; 85 (3): 664-6.

Schnepp RW, Bosse KR, Maris JM. Improving patient outcomes with cancer genomics: Unique opportunities and challenges in pediatric oncology. JAMA. 2015; 314 (9): 881-3.

2014

Diskin SJ, Capasso M, Diamond M, Oldridge D, Bosse KR, Iolascon A, Hakonarson H, Devoto M, Maris JM. Rare variants in TP53 confer susceptibility to neuroblastoma. The Journal of the National Cancer Institute. 2014; 106 (4).

Bosse KR, Shukla A, Pawel B, Chikwava KR, Santi M, Took L, Castagna K, Biegel J, Bagatell R. Malignant rhabdoid tumor of the bladder and ganglioglioma in a 14 year-old male with a germline 22q11.2 deletion. Cancer Genetics. 2014; 207 (9): 415-9.

Abstracts

2016

Bosse KR, Raman P, Sussman R, Randall M, Martinez D, Zhu Z, Harenza JL, Pawel B, Bhatti  T, Khan J, Dimitrov D, Mackall C, and Maris JM. GPC2 is a putative oncogene and candidate immunotherapeutic target in high-risk neuroblastoma, Presented at the Advances in Neuroblastoma Research Congress, June 2016.

Sussman RT, Randall MR, Huang K, Bosse K, Feng Y, Wang Y, Zhu Z, Dimitrov DS, and Maris JM. A CD56 (NCAM1) targeting antibody-drug conjugate is potently effective in preclinical models of high-risk neuroblastoma, Presented at the Advances in Neuroblastoma Research Congress, June 2016.

Bosse KR, Raman P, Sussman R, Randall M, Martinez D, Zhu Z, Pawel B, Bhatti T, Khan J, Dimitrov D, Mackall C, and Maris JM. GPC2 is a candidate immunotherapeutic target and putative oncogene in high-risk neuroblastoma and other pediatric cancers, Presented at the Children's Hospital of Philadelphia Research Poster Day, February 2016.

2015

Bosse KR, Raman P, Sussman R, Randall M, Martinez D, Zhu Z, Pawel B, Bhatti T, Khan J, Dimitrov D, Mackall C, and Maris JM. GPC2 is a candidate immunotherapeutic target and putative oncogene in high-risk neuroblastoma and other pediatric cancers, Presented at the AACR Advances in Pediatric Cancer Research Conference, November 2015.

Bosse KR, Raman P, Sussman R, Martinez D, Pawel B, and Maris JM. The Identification of  SLC10A4 and GPC2 as Putative Immunotherapeutic Targets in High Risk Neuroblastoma Using an Unbiased and Integrated Transcriptome, Genomics, and Functional Approach, Presented at the Children's Hospital of Philadelphia Research Poster Day, February 2015.

2014

Maris J, Wood A, Schnepp R, Russell M, Cole K, Oldridge D, Bosse K, Winter C, Rahman N, Capasso M, Hakonarson H, Le H, Devoto M, Diskin SJ. A Genome-Wide Association Study (GWAS) Identifies Susceptibility Alleles within Neuroblastoma Oncogenes and Tumor Suppressors: An Explanation for the Paucity of Somatic Mutations?, Presented at the Advances in Neuroblastoma Research Congress, May 2014.

Posters and Presentations

2016 

Bosse KR, Raman P, Sussman R, Randall M, Martinez D, Zhu Z, Pawel B, Bhatti T, Khan J, Dimitrov D, Mackall C, and Maris JM. GPC2 is a candidate immunotherapeutic target and putative oncogene in high-risk neuroblastoma and other pediatric cancers, Presented at the Children's Hospital of Philadelphia Research Poster Day, February 2016.

2015

Bosse KR, Raman P, Sussman R, Randall M, Martinez D, Zhu Z, Pawel B, Bhatti T, Khan J, Dimitrov D, Mackall C, and Maris JM. GPC2 is a candidate immunotherapeutic target and putative oncogene in high-risk neuroblastoma and other pediatric cancers, Presented at the AACR Advances in Pediatric Cancer Research Conference, November 2015.

Bosse KR, Raman P, Sussman R, Martinez D, Pawel B, and Maris JM. The Identification of SLC10A4 and GPC2 as Putative Immunotherapeutic Targets in High Risk Neuroblastoma Using an Unbiased and Integrated Transcriptome, Genomics, and Functional Approach, Presented at the Children's Hospital of Philadelphia Research Poster Day, February 2015.

Invited Lectures

2016

Bosse KR, Raman P, Sussman R, Randall M, Martinez D, Zhu Z, Harenza JL, Pawel B, Bhatti  T, Khan J, Dimitrov D, Mackall C, and Maris JM. GPC2 is a putative oncogene and candidate immunotherapeutic target in high-risk neuroblastoma, Presented at the Advances in Neuroblastoma Research Congress, June 2016.

Sussman RT, Randall MR, Huang K, Bosse K, Feng Y, Wang Y, Zhu Z, Dimitrov DS, and Maris JM. A CD56 (NCAM1) targeting antibody-drug conjugate is potently effective in preclinical models of high-risk neuroblastoma, Presented at the Advances in Neuroblastoma Research Congress, June 2016.

2015

Bosse KR, Raman P, Sussman R, Randall M, Martinez D, Zhu Z, Pawel B, Bhatti T, Khan J, Dimitrov D, Mackall C, and Maris JM. GPC2 is a candidate immunotherapeutic target and putative oncogene in high-risk neuroblastoma and other pediatric cancers, Presented at the AACR Advances in Pediatric Cancer Research Conference, November 2015.

2014

Maris J, Wood A, Schnepp R, Russell M, Cole K, Oldridge D, Bosse K, Winter C, Rahman N, Capasso M, Hakonarson H, Le H, Devoto M, Diskin SJ. A Genome-Wide Association Study (GWAS) Identifies Susceptibility Alleles within Neuroblastoma Oncogenes and Tumor Suppressors: An Explanation for the Paucity of Somatic Mutations?, Presented at the Advances in Neuroblastoma Research Congress, May 2014.

Awards and Honors

2016, Damon Runyon Physician-Scientist Training Award

2016, Alex’s Lemonade Stand Young Investigator Award

2016, Abramson Cancer Center’s Paul Calabresi Career Development Award for Clinical Oncology (K12)

2015, AACR/Aflac Scholar-in-Training Award

2015, Children’s Hospital of Philadelphia Research Day Poster Prize

2009, Children’s Hospital of Philadelphia Research Day Poster Prize

2009, NIDDK Short-Term Research Training Fellowship

2008, HHMI Medical Student Research Training Fellowship

2006-2010, Dr. Clinton Noyes and Alice F. Peters Medical Scholarship

2002, Phi Beta Kappa

2002, Merck Index Award

2001, Philip W. Meserve Prize in Chemistry

2001, Rick Scala Coach’s Award, Bowdoin College Rugby

2001, Pfizer Summer Undergraduate Research Fellowship

2001, Surdna Foundation Undergraduate Research Fellowship

2000, James Stacy Coles Research Fellowship in Chemistry

1999-2001, Sarah and James Bowdoin Book Award

Editorial and Academic Positions

Editorial Positions

Ad Hoc Reviewer

2016, Cancer Letters

2015-2016, Cancer Cell

2015, Current Genomics

Leadership and Memberships

Memberships in Professional Organizations

2014-present, American Association for Cancer Research

2013-present, American Society of Pediatric Hematology/Oncology

2013-present, American Society of Clinical Oncology